CAR-T Cell Therapy Market Size, Technology, Devices, Challenges 2024–2032
The CAR-T cell therapy market was valued at USD 2.72 billion in 2022 and is anticipated to reach USD 14.42 billion by 2030, with a CAGR of 18.5% from 2023 to 2030. North America dominated the global market with a share of 64.33% in 2022.
In a recent study, Fortune Business Insights presents the nitty-gritty of the global CAR-T Cell Therapy Market considering 2024–2032 as the stipulated timeframe. The business report highlights the drivers, restraints, opportunities and trends affecting market growth. Further, all the market shares associated with the market as well as the segments are expressed in terms of value and volume.
Request a Free Sample PDF Brochure of CAR-T Cell Therapy Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/108455
The CAR-T Cell Therapy Market study outlines the key regions of North America, Latin America, Europe, East Asia, Japan along with the countries contributing the most in the respective regions. The report presents detailed insights about each market player, including SWOT analysis, main market information, market share, revenue, pricing and gross margin. Prominent players covered in this research are
- Gilead Sciences, Inc. (U.S.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Johnson & Johnson Services, Inc. (Janssen Global Services, LLC) (U.S.)
- Caribou Biosciences, Inc. (U.S.)
- CARsgenTherapeutics Co., Ltd (China)
- JW Therapeutics (Shanghai) Co., Ltd. (China)
- Cartesian Therapeutics, Inc. (U.S.)
- Aurora Biopharma (U.S.)
Market Dynamics
The global prevalence of cancer is a major driver for the growth of the CAR-T cell therapy market. The availability of Patient Assistance Programs (PAPs) and government initiatives to raise awareness about cancer also contribute to this growth. Growing awareness about blood cancers due to government, healthcare, and market initiatives is leading to higher diagnosis and treatment rates.
The insights for each vendor consist of:
- Company profile
- SWOT analysis
- Main market information
- Market share
- Revenue, pricing and gross margin
Speak to Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/108455
Crucial insights in the CAR-T Cell Therapy Market research:
- Underlying macro- and microeconomic factors impacting the growth of the CAR-T Cell Therapy Market.
- Basic overview of CAR-T Cell Therapy Market, including market definition, classification, and applications.
- Scrutinization of each CAR-T Cell Therapy Market player based on mergers & acquisitions, R&D projects, and product launches.
- Adoption trend of CAR-T Cell Therapy Market across various industries.
- Important regions and countries offering lucrative opportunities to CAR-T Cell Therapy Market stakeholders.
Segmentation Analysis:
By Drug Type
Axicabtagene Ciloleucel (Yescarta)
Brexucabtagene Autoleucel (Tecartus)
Ciltacabtagene Autoleucel (Carvykti)
Idecabtagene Vicleucel (Abecma)
Lisocabtagene Maraleucel (Breyanzi)
Tisagenlecleucel (Kymriah)
Others
By Indication
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
By End-user
Hospitals
Oncology Treatment Centers
Important regions covered in the CAR-T Cell Therapy Market report include:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Order a copy of this research report at — https://www.fortunebusinessinsights.com/checkout-page/108455
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
Email: sales@fortunebusinessinsights.com
Phone: US: +1 424 253 0390, UK: +44 2071 939123, APAC: +91 74